PDCD2

Across TCGA pan-cancer cohorts, PDCD2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of PDCD2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where PDCD2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PDCD2 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LSCC, HNSC, and PDAC are the cancer types where PDCD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PDCD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	+0.465	<.001	8	view →
HNSC	All	All	+0.142	.004	5	view →
PDAC	Male	All	−0.464	.003	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

PDCD2–LSCC

Open the LSCC breakdown →